Abstract
The TRAVERSE open-label extension study (NCT02134028) assessed long-term safety and efficacy of dupilumab in patients aged ≥12 years with moderate-to-severe asthma who had completed a parent dupilumab asthma study. This post-hoc analysis assessed the long-term effect (up to 48 weeks) of dupilumab on asthma control in patients with uncontrolled, moderate-to-severe, type 2 asthma (blood eosinophils ≥150 cells/μL or FeNO ≥25 ppb) at parent study baseline (PSBL) who enrolled in TRAVERSE from phase 3 QUEST (NCT02414854) and the number of sick leave days due to severe exacerbations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
